High-end suppliers of chemical, biological reagents, pharmaceutical intermediates and APIs
Current Location:Home > Newsletter


Date of publication:2020/3/23 16:12:09
Huateng Pharma Coronavirus treatment


COVID-19 Research?

The 2019 novel coronavirus (COVID-19) has spread rapidly since its recent identification in patients with severe pneumonia in Wuhan, China. The pandemic has spread to over 150 countries and territories. Vaccines and treatment options for COVID-19 are currently being investigated around the world. There’s some evidence that certain medications may have the potential to be effective with regard to preventing illness or treating the symptoms of COVID-19.

In this phase of growing threat, Huateng Pharma plays its parts by providing the necessary drug intermediates which might be used for the research purpose of coronavirus treatment. 
We are able to provide the production of remdesivir intermediates and API for research use with capacities varying from gram to kilograms. Learn more>>


Remdesivir Intermediates

Remdesivir, also known as GS-5734, is a novel antiviral drug in the class of nucleotide analogs developed by Gilead Sciences. In February 2020 Remdesivir was being studied for experimental treatment of the emergent COVID-19 (novel coronavirus) disease.

CAS# 55094-52-5


Read more


CAS# 159326-68-8


Read more

CAS# 1191237-69-0



Read more

CAS# 1355357-49-1

Remdesivir N-4 intermediate

Read more


CAS# 1191237-80-5

Remdesivir N-2 intermediate

Read more

CAS# 946511-97-3

Remdesivir amino ester compound

Read more

CAS# 1355049-92-1

Remdesivir Chloro compound

Read more


CAS # 1191578-98-9

Read more


CAS # 1809249-37-3

Remdesivir API

Read more

Baloxavir Marboxil Intermediates

CAS No. 1985606-14-1

CAS No. 1985607-83-7

CAS No. 2136287-66-4

CAS No. 2136287-68-6

Read more


Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, P.R. China.



+86 0731 89916275


Official Website:

Remdesivir Intermediates>